Given that the global IBS prevalence is approximately 4% under Rome IV criteria, the post-COVID increase represents a substantial disease burden
Franzman, M.R., Burnell, K.K., Dehkordi-Vakil, F.H., Guthmiller, J.M., Dawson, D.V., and Brogden, K.A., Int
How we reviewed this article: Current Version October 03, 2025 Written By John DiBella Fact-checked By Dr
GIP is also implicated in nausea attenuation, which may be why GLP-1/GIP dual agonists like tirzepatide have a slightly better GI tolerability profile than pure GLP-1 agonists
Each serum contains 1 fl oz / 30 mL and is packaged in your choice of premium glass dropper bottle
For inflammatory bowel disease research, both peptides show promise with complementary mechanisms